These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 32013831)

  • 1. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    Chen Z; Wang X; Li X; Zhou Y; Chen K
    J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
    Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
    J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
    Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
    Jin J; Zhang W; Ji W; Yang F; Guan X
    Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do platinum salts fit all triple negative breast cancers?
    Gerratana L; Fanotto V; Pelizzari G; Agostinetto E; Puglisi F
    Cancer Treat Rev; 2016 Jul; 48():34-41. PubMed ID: 27343437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
    Desai NV; Tan AR
    JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Lips EH; Benard-Slagter A; Opdam M; Scheerman CE; Wesseling J; Hogervorst FBL; Linn SC; Savola S; Nederlof PM
    Breast Cancer Res; 2020 Jul; 22(1):79. PubMed ID: 32711554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination deficiency in triple negative breast cancer.
    Belli C; Duso BA; Ferraro E; Curigliano G
    Breast; 2019 Jun; 45():15-21. PubMed ID: 30818144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and epigenomic
    Menghi F; Banda K; Kumar P; Straub R; Dobrolecki L; Rodriguez IV; Yost SE; Chandok H; Radke MR; Somlo G; Yuan Y; Lewis MT; Swisher EM; Liu ET
    Sci Transl Med; 2022 Jul; 14(652):eabn1926. PubMed ID: 35857626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.